We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioFocus Creates Novel Diverse Screening Library
Product News

BioFocus Creates Novel Diverse Screening Library

BioFocus Creates Novel Diverse Screening Library
Product News

BioFocus Creates Novel Diverse Screening Library


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BioFocus Creates Novel Diverse Screening Library"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioFocus has announced that it has enhanced its diverse screening library through new compound supply agreements with InterBioScreen, Enamine and ChemBridge.

BioFocus now offers one of the most powerful screening platforms in the industry with over 900,000 unique chemical compounds and approximately 100,000 probes from natural sources.

Under the agreements BioFocus has selected a total of 350,000 new compounds. These compounds will replace a portion of the current screening library, resulting in a collection with significantly increased novelty, structural diversity and lead likeness, while increasing its overall solubility profile.

“Integrating our screening collection with our assay expertise has provided our clients with a platform that has the size and flexibility to deliver on their hit-finding campaigns”, said Kate Hilyard, Vice President Biological Sciences BioFocus.

Hilyard continued, “This latest round of compound acquisition demonstrates our commitment to maintaining our reputation as a leading partner in drug discovery”.

Advertisement